
David V Sheehan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4846255/publications.pdf Version: 2024-02-01



Πλυίο V Sheehan

#	Article	IF	CITATIONS
1	The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. European Psychiatry, 1997, 12, 224-231.	0.2	2,824
2	The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. European Psychiatry, 1997, 12, 232-241.	0.2	1,682
3	Reliability and Validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). Journal of Clinical Psychiatry, 2010, 71, 313-326.	2.2	1,140
4	Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale. International Journal of Psychiatry in Medicine, 1997, 27, 93-105.	1.8	845
5	Treatment of Endogenous Anxiety With Phobic, Hysterical, and Hypochondriacal Symptoms. Archives of General Psychiatry, 1980, 37, 51.	12.3	678
6	Effect of Hypericum perforatum (St John's Wort) in Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2002, 287, 1807.	7.4	417
7	Mental Disorders and Disability Among Patients in a Primary Care Group Practice. American Journal of Psychiatry, 1997, 154, 1734-1740.	7.2	354
8	Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. International Clinical Psychopharmacology, 2008, 23, 70-83.	1.7	319
9	Nicotinic acetylcholine receptors as targets for antidepressants. Molecular Psychiatry, 2002, 7, 525-535.	7.9	261
10	A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. Eating and Weight Disorders, 2016, 21, 353-364.	2.5	243
11	Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety Disorder. American Journal of Psychiatry, 2000, 157, 968-974.	7.2	222
12	DSM-IH-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI. European Psychiatry, 1998, 13, 26-34.	0.2	221
13	Panic Attacks and Phobias. New England Journal of Medicine, 1982, 307, 156-158.	27.0	216
14	Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry, 2003, 160, 749-756.	7.2	185
15	Some Biochemical Correlates of Panic Attacks with Agoraphobia and Their Response to a New Treatment. Journal of Clinical Psychopharmacology, 1984, 4, 66-75.	1.4	142
16	Physician Substance Use by Medical Specialty. Journal of Addictive Diseases, 1999, 18, 23-37.	1.3	138
17	Is Buspirone Effective for Panic Disorder?. Journal of Clinical Psychopharmacology, 1990, 10, 3-11.	1.4	125
18	Comparing the Effects of Antidepressants: Consensus Guidelines for Evaluating Quantitative Reviews of Antidepressant Efficacy. Neuropsychopharmacology, 2005, 30, 445-460.	5.4	120

#	Article	IF	CITATIONS
19	Humanistic and economic burden of generalized anxiety disorder in North America and Europe. Journal of Affective Disorders, 2012, 140, 103-112.	4.1	117
20	The relative efficacy of highâ€dose buspirone and alprazolam in the treatment of panic disorder: a doubleâ€blind placeboâ€controlled study. Acta Psychiatrica Scandinavica, 1993, 88, 1-11.	4.5	112
21	Age of onset of phobic disorders: A reevaluation. Comprehensive Psychiatry, 1981, 22, 544-553.	3.1	108
22	Restoring function in major depressive disorder: A systematic review. Journal of Affective Disorders, 2017, 215, 299-313.	4.1	108
23	Resident physician substance use, by specialty. American Journal of Psychiatry, 1992, 149, 1348-1354.	7.2	104
24	Generalized anxiety disorder: comorbidity, comparative biology and treatment. International Journal of Neuropsychopharmacology, 2002, 5, 315-325.	2.1	102
25	Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development. Journal of Clinical Psychiatry, 2010, 71, e1-e21.	2.2	99
26	Multicenter, Double-Blind, Placebo-Controlled Study of Mecamylamine Monotherapy for Tourette's Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 1103-1110.	0.5	94
27	Suicidal ideation in primary care. Journal of General Internal Medicine, 1996, 11, 447-453.	2.6	92
28	Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. International Clinical Psychopharmacology, 2011, 26, 75-83.	1.7	92
29	Antidepressant Use in Geriatric Populations: The Burden of Side Effects and Interactions and Their Impact on Adherence and Costs. American Journal of Geriatric Psychiatry, 2011, 19, 211-221.	1.2	88
30	Differences in Medication AdherenceÂand Healthcare ResourceÂUtilization Patterns. CNS Drugs, 2008, 22, 963-973.	5.9	82
31	The Classification of Phobic Disorders. International Journal of Psychiatry in Medicine, 1983, 12, 243-266.	1.8	78
32	A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2014, 34, 47-56.	1.4	76
33	Neuronal nicotinic receptor inhibition for treating mood disorders preliminary controlled evidence with mecamylamine. Depression and Anxiety, 2002, 16, 89-92.	4.1	73
34	The Tourette's Disorder Scale (TODS). Assessment, 2003, 10, 273-287.	3.1	71
35	Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment. Journal of Clinical Psychiatry, 2011, 72, 914-928.	2.2	70
36	Lack of Efficacy of a New Antidepressant (Bupropion) in the Treatment of Panic Disorder with Phobias. Journal of Clinical Psychopharmacology, 1983, 3, 28???31.	1.4	68

#	Article	IF	CITATIONS
37	Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder. Journal of Clinical Psychiatry, 2005, 66, 34-40.	2.2	66
38	Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology, 2009, 29, 222-230.	1.4	64
39	Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. European Neuropsychopharmacology, 2012, 22, 847-857.	0.7	63
40	Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. Journal of Psychiatric Research, 2002, 36, 209-217.	3.1	61
41	Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. Journal of Affective Disorders, 2009, 115, 376-385.	4.1	59
42	Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development. Journal of Clinical Psychiatry, 2010, 71, 1040-1046.	2.2	57
43	Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine. Neuropsychopharmacology, 2008, 33, 3201-3212.	5.4	55
44	The Classification of Anxiety and Hysterical States. Part II. Toward a More Heuristic Classification. Journal of Clinical Psychopharmacology, 1982, 2, 386???393.	1.4	54
45	The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?. Innovations in Clinical Neuroscience, 2014, 11, 66-80.	0.1	53
46	Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Journal of Clinical Psychiatry, 2005, 66, 34-40.	2.2	51
47	The Classification of Anxiety and Hysterical States. Part I. Historical Review and Empirical Delineation. Journal of Clinical Psychopharmacology, 1982, 2, 235???244.	1.4	47
48	Benzodiazepines in panic disorder and agoraphobia. Journal of Affective Disorders, 1987, 13, 169-181.	4.1	47
49	Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. European Neuropsychopharmacology, 2012, 22, 858-866.	0.7	46
50	The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacology Bulletin, 2009, 42, 5-22.	0.0	45
51	Monoamine Oxidase Inhibitors: Prescription and Patient Management. International Journal of Psychiatry in Medicine, 1981, 10, 99-121.	1.8	44
52	Immunological response to stress in agoraphobia and panic attacks. Biological Psychiatry, 1986, 21, 768-774.	1.3	40
53	Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. Journal of Affective Disorders, 2013, 145, 83-94.	4.1	39
54	A Three-Year Follow-Up of Hypnosis and Restricted Environmental Stimulation Therapy for Smoking. International Journal of Clinical and Experimental Hypnosis, 1986, 34, 169-181.	1.8	38

#	Article	IF	CITATIONS
55	Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Review of Neurotherapeutics, 2009, 9, 1147-1158.	2.8	38
56	A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1990, 14, 929-939.	4.8	34
57	False positive results: a challenge for psychiatric screening in primary care. American Journal of Psychiatry, 1997, 154, 1462-1464.	7.2	34
58	Tricyclic antidepressants in the treatment of panic and anxiety disorders. Psychosomatics, 1986, 27, 10-16.	2.5	33
59	Family Impact of Tourette's Syndrome. Journal of Child and Family Studies, 2001, 10, 477-483.	1.3	32
60	An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. International Clinical Psychopharmacology, 2009, 24, 43-60.	1.7	32
61	The Psychological and Medical Factors Associated With Untreated Binge Eating Disorder. primary care companion for CNS disorders, The, 2015, 17, .	0.6	31
62	Perceived stress in anxiety disorders and the general population: A study of the Sheehan stress vulnerability scale. Psychiatry Research, 2007, 151, 249-254.	3.3	27
63	Monoamine Oxidase Inhibitors and Alprazolam in the Treatment of Panic Disorder and Agoraphobia. Psychiatric Clinics of North America, 1985, 8, 49-62.	1.3	25
64	The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain and Behavior, 2017, 7, e00622.	2.2	25
65	Diagnostic Errors of Primary Care Screens for Depression and Panic Disorder. International Journal of Psychiatry in Medicine, 1999, 29, 1-11.	1.8	24
66	A diagnostic aid for detecting (DSM-IV) mental disorders in primary care. General Hospital Psychiatry, 1998, 20, 1-11.	2.4	23
67	A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone Monotherapy in Bipolar Disorder With Co-Occurring Lifetime Panic or Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 2014, 75, 77-84.	2.2	23
68	Evaluating the Economic Consequences of Early Antidepressant Treatment Discontinuation. Journal of Clinical Psychopharmacology, 2004, 24, 544-548.	1.4	22
69	Behavioral Consequences of Job-Related Stress among Resident Physicians: The Mediating Role of Psychological Strain. Psychological Reports, 1991, 69, 339-349.	1.7	21
70	Snorting Benzodiazepines. American Journal of Drug and Alcohol Abuse, 1991, 17, 457-468.	2.1	21
71	Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale. International Clinical Psychopharmacology, 2012, 27, 1.	1.7	21
72	The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Current Medical Research and Opinion, 2008, 24, 2457-2466.	1.9	20

#	Article	IF	CITATIONS
73	Generalized anxiety disorder. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 343-362.	1.8	20
74	Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. Human Psychopharmacology, 2016, 31, 53-63.	1.5	20
75	Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 2016, 77, 1687-1694.	2.2	20
76	Current approaches to the pharmacologic treatment of anxiety disorders. Psychopharmacology Bulletin, 2007, 40, 98-109.	0.0	20
77	Relations among Stressors, Strains, and Substance Use among Resident Physicians. Substance Use and Misuse, 1992, 27, 979-994.	0.6	19
78	Dental anxiety ―the development of a measurement model. Acta Psychiatrica Scandinavica, 1986, 73, 559-565.	4.5	15
79	SOCIAL ANXIETY DISORDER. Medical Clinics of North America, 2001, 85, 711-733.	2.5	15
80	Sheehan Suicidality Tracking Scale (S-STS): Reliability, convergent and discriminative validity in young Italian adults. Comprehensive Psychiatry, 2013, 54, 842-849.	3.1	15
81	Panic and Phobias: Empirical Evidence of Models and Longterm Effects of Behavioral Treatments. American Journal of Psychiatry, 1990, 147, 1084-1085.	7.2	15
82	Comparative Validation of the S-STS, the ISST-Plus, and the C-SSRS for Assessing the Suicidal Thinking and Behavior FDA 2012 Suicidality Categories. Innovations in Clinical Neuroscience, 2014, 11, 32-46.	0.1	15
83	Status Update on the Sheehan-Suicidality Tracking Scale (S-STS) 2014. Innovations in Clinical Neuroscience, 2014, 11, 93-140.	0.1	15
84	A Combination Drug Treatment for Acute Common Migraine. Headache, 1986, 26, 231-236.	3.9	14
85	Relationship between major depressive disorder and associated painful physical symptoms. International Clinical Psychopharmacology, 2013, 28, 330-338.	1.7	14
86	Is There Value in Asking the Question "Do you think you would be better off dead?" in Assessing Suicidality? A Case Study. Innovations in Clinical Neuroscience, 2014, 11, 182-90.	0.1	14
87	Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. Journal of Affective Disorders, 2016, 204, 40-47.	4.1	13
88	The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. Psychopharmacology Bulletin, 2007, 40, 63-81.	0.0	13
89	Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. International Clinical Psychopharmacology, 2009, 24, 61-86.	1.7	12
90	Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): Data from a randomized-withdrawal, placebo-controlled maintenance study. Journal of Affective Disorders, 2013, 151, 906-913.	4.1	12

#	Article	IF	CITATIONS
91	Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. American Journal of Managed Care, 2005, 11, S354-61.	1.1	12
92	Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. Human Psychopharmacology, 2011, 26, 242-251.	1.5	11
93	Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry, 2009, 6, 20-33.	0.3	11
94	Simple Measures of Hopelessness and Impulsivity are Associated with Acute Suicidal Ideation and Attempts in Patients in Psychiatric Crisis. Innovations in Clinical Neuroscience, 2014, 11, 47-53.	0.1	11
95	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. Innovations in Clinical Neuroscience, 2016, 13, 20-31.	0.1	11
96	Influence of Psychosocial Factors on Wart Remission. American Journal of Clinical Hypnosis, 1978, 20, 160-164.	0.6	10
97	An open-label study of tiagabine in panic disorder. Psychopharmacology Bulletin, 2007, 40, 32-40.	0.0	10
98	The diagnosis and drug treatment of anxiety disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1983, 7, 599-603.	4.8	9
99	A Case of Bupropion-Induced Seizure. Journal of Nervous and Mental Disease, 1986, 174, 496-498.	1.0	9
100	Empirical assessment of spiegel's hypnotic induction profile and eye-roll hypothesis. International Journal of Clinical and Experimental Hypnosis, 1979, 27, 103-110.	1.8	8
101	Adinazolam sustained release formulation in the treatment of generalized anxiety disorder. Journal of Anxiety Disorders, 1990, 4, 239-246.	3.2	8
102	Recent developments in the treatment of panic disorder. Acta Psychiatrica Scandinavica, 1987, 76, 75-83.	4.5	6
103	Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. International Clinical Psychopharmacology, 2012, 27, 239-248.	1.7	6
104	Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2016, 77, 1080-1086.	2.2	6
105	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. Innovations in Clinical Neuroscience, 2020, 17, 30-40.	0.1	6
106	Patients with obsessive-compulsive disorder vs depression have comparable health care costs: a retrospective claims analysis of Florida Medicaid enrollees. Annals of Clinical Psychiatry, 2011, 23, 285-96.	0.6	6
107	Adinazolam sustained release formulation in the treatment of panic disorder: a pilot study. Irish Journal of Psychological Medicine, 1990, 7, 124-128.	1.0	5
108	Prevalence of Substance Use Among U.S. Physicians. Obstetrical and Gynecological Survey, 1992, 47, 771-773.	0.4	5

#	Article	IF	CITATIONS
109	Adequacy of Pharmacotherapy Among Medicaid-Enrolled Patients Newly Diagnosed with Obsessive-Compulsive Disorder. CNS Spectrums, 2009, 14, 695-703.	1.2	5
110	Psychiatric Aspects of Oral Contraceptive Use. Psychiatric Annals, 1976, 6, 81-99.	0.1	5
111	Linguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STS). Innovations in Clinical Neuroscience, 2014, 11, 141-63.	0.1	5
112	Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical Review. Innovations in Clinical Neuroscience, 2014, 11, 54-65.	0.1	5
113	Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials. Innovations in Clinical Neuroscience, 2018, 15, 22-29.	0.1	5
114	Paroxetine treatment of generalized anxiety disorder. Psychopharmacology Bulletin, 2003, 37 Suppl 1, 64-75.	0.0	5
115	Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. European Psychiatry, 2013, 28, 190-196.	0.2	4
116	Do the Five Combinations of Suicidal Ideation in the FDA 2012 Draft Guidance Document and the C-SSRS Adequately Cover All Suicidal Ideation Combinations in Practice? A Case Study. Innovations in Clinical Neuroscience, 2014, 11, 172-8.	0.1	4
117	An Open Study Examining the Diagnosis of Anxiety and the Use of Buspirone in a Primary Care Environment. Drug Investigation, 1989, 1, 3-10.	0.6	3
118	Content validity of the Sheehan Irritability Scale in patients with major depressive disorder. International Clinical Psychopharmacology, 2016, 31, 110-117.	1.7	3
119	Classification of Anxiety Disorders. , 1985, , 711-716.		3
120	Importance of Restoring Function in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2016, 77, e908-e908.	2.2	3
121	Medical Evaluation of the Anxious Patient. Psychiatric Annals, 1988, 18, 176-181.	0.1	3
122	Panic Attacks and Phobias. New England Journal of Medicine, 1983, 308, 341-343.	27.0	2
123	Single ion gas chromatographic/mass spectroscopic quantitative analysis of environmental CO ₂ in agoraphobic environments. Anxiety, 1994, 1, 275-277.	0.4	2
124	Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics. Anxiety, 1996, 2, 40-46.	0.4	2
125	Diagnosis and Treatment of Anxiety Disorders in Children and Adolescents. Psychiatric Annals, 1988, 18, 146-157.	0.1	2
126	Perspectives: Substance Use Among Senior Medical Students: A Survey of 23 Medical Schools. Journal of Addictions Nursing, 1992, 4, 72-79.	0.4	1

#	Article	IF	CITATIONS
127	Cross-Validation of the Arabic Mini International Neuropsychiatric Interview, Module K, for Diagnosis of Schizophrenia and the Arabic Positive and Negative Syndrome Scale. Journal of Psychopathology and Behavioral Assessment, 2020, 42, 139-149.	1.2	1
128	Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale. International Journal of Methods in Psychiatric Research, 2021, 30, e1849.	2.1	1
129	The complexity of assessing overall severity of suicidality: a case study. Innovations in Clinical Neuroscience, 2014, 11, 164-71.	0.1	1
130	Is a count of suicidal ideation and behavior events useful in assessing global severity of suicidality? A case study. Innovations in Clinical Neuroscience, 2014, 11, 179-81.	0.1	1
131	Can you recommend some literature on panic attacks and phobias that would help in their understanding and management?. Journal of Clinical Psychopharmacology, 1982, 2, 20s.	1.4	0
132	Can you recommend a management strategy to guide clinicians in their implementation of the various treatment modalities for a patient with spontaneous anxiety attacks and multiple phobias?. Journal of Clinical Psychopharmacology, 1982, 2, 19s.	1.4	0
133	How should alprazolam be withdrawn when a patient has completed his or her trial on the drug?. Journal of Clinical Psychopharmacology, 1982, 2, 17s.	1.4	Ο
134	Should not panic disorders be classified as panic disorders, with or without agoraphobia, rather than agoraphobia, with or without panic attacks (as in DSM-III)?. Journal of Clinical Psychopharmacology, 1982, 2, 18s.	1.4	0
135	Agoraphobia: Multiple Perspectives on Theory and Treatment. American Journal of Psychiatry, 1985, 142, 511-511.	7.2	0
136	Diagnosis and treatment of pathological anxiety. Stress and Health, 1987, 3, 21-32.	0.5	0
137	No: Efforts to relieve human suffering deserve rewards. Western Journal of Medicine, 2001, 175, 365-365.	0.3	0
138	A 37-year-old Woman With Treatment-resistant Panic Disorder - or Is it Bipolar Anxiety?. Psychiatric Annals, 2004, 34, 904-910.	0.1	0
139	Rating Scales and Diagnostic Schemata. , 2014, , 1-3.		Ο
140	Panic and Other Anxiety Disorders: Diagnosis and Treatment. , 1985, , 775-781.		0
141	How the Timing of a Patient's Self-ratings of Suicidality and the Relationship to the Recipient Affect Patient Responses: A Case Study. Innovations in Clinical Neuroscience, 2014, 11, 191-3.	0.1	0
142	Pilot Mental Health Survey, Nepal: Lessons Learned for Survey Design and Instrumentation. Innovations in Clinical Neuroscience, 2020, 17, 17-23.	0.1	0
143	Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment. Managed Care Quarterly, 2002, 10, 21-31.	0.2	0
144	Improved tolerability and increased length of therapy. Managed Care, 2003, 12, 23-5.	0.3	0

DAVID V SHEEHAN	
UAVID V JALEAAN	

#	Article	IF	CITATIONS
145	Panic: Facing Fears, Phobias, and Anxiety. American Journal of Psychiatry, 1987, 144, 1356-b-1357.	7.2	О